Cargando…

Risk of Gastrointestinal Adverse Events in Cancer Patients Treated With Immune Checkpoint Inhibitor Plus Chemotherapy: A Systematic Review and Meta-Analysis

Background: The combination of immune checkpoint inhibitors (ICIs) and chemotherapy can improve clinical outcomes in the treatment of various tumors, but may also be associated with more adverse events (AEs). We performed a systematic review and meta-analysis to characterize the risk of gastrointest...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yang, Wenhan, Men, Peng, Xue, Huimin, Jiang, Mingyan, Luo, Qiuhua
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7076172/ https://www.ncbi.nlm.nih.gov/pubmed/32211312 http://dx.doi.org/10.3389/fonc.2020.00197

Ejemplares similares

Risk factors for cardiovascular adverse events from immune checkpoint inhibitors
por: Luo, Lingli, et al.
Publicado: (2023)

Radiotherapy plus immune checkpoint inhibitor in prostate cancer
por: Li, Tianjie, et al.
Publicado: (2023)

Prognostic Significance of SUVmax Combined With Lactate Dehydrogenase in Advanced Lung Cancer Patients Treated With Immune Checkpoint Inhibitor Plus Chemotherapy: A Retrospective Study
por: Ke, Linping, et al.
Publicado: (2021)

Incidence of Skin and Respiratory Immune-Related Adverse Events Correlates With Specific Tumor Types in Patients Treated With Checkpoint Inhibitors
por: Rose, Lynn M., et al.
Publicado: (2021)

Risk of Cardiac Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-Analysis
por: Hu, Jiexuan, et al.
Publicado: (2021)

Management of gastrointestinal adverse events induced by immune-checkpoint inhibitors
por: Wang, Zheng-Hang, et al.
Publicado: (2018)

Gastrointestinal adverse events associated with immune checkpoint inhibitor therapy
por: Rajha, Eva, et al.
Publicado: (2019)

Editorial: Management of Immune-Related Adverse Events for Patients Undergoing Treatment With Checkpoint Inhibitors
por: Rapoport, Bernardo Leon
Publicado: (2019)

Biomarkers of Checkpoint Inhibitor Induced Immune-Related Adverse Events—A Comprehensive Review
por: Hommes, Josefien W., et al.
Publicado: (2021)

Predicting survival of NSCLC patients treated with immune checkpoint inhibitors: Impact and timing of immune-related adverse events and prior tyrosine kinase inhibitor therapy
por: Sayer, Michael R., et al.
Publicado: (2023)

Treatment-Related Adverse Events of Combination Immune Checkpoint Inhibitors: Systematic Review and Meta-Analysis
por: Park, Robin, et al.
Publicado: (2020)

Immune checkpoint inhibitor-associated gastrointestinal and hepatic adverse events and their management
por: Shivaji, Uday N., et al.
Publicado: (2019)

Is De-escalated Bisphosphonates Therapy a Suitable Alternative to Standard Dosing in Malignant Tumor Patients With Bone Metastases: A Systematic Review and Meta-Analysis
por: Luo, Qiuhua, et al.
Publicado: (2019)

Treatment-Related Serious Adverse Events of Immune Checkpoint Inhibitors in Clinical Trials: A Systematic Review
por: Ouyang, Tao, et al.
Publicado: (2021)

Immune-related adverse events of anti-PD-1 immune checkpoint inhibitors: a single center experience
por: Sebestyén, Enikő, et al.
Publicado: (2023)

Neoadjuvant Immune Checkpoint Inhibitors Plus Chemotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma: Perioperative and Survival Outcomes
por: Ma, Xiao, et al.
Publicado: (2022)

Pancreatic adverse events in patients treated with immune checkpoint inhibitors
por: Hana, Caroline, et al.
Publicado: (2023)

Correlation of the gut microbiome and immune-related adverse events in gastrointestinal cancer patients treated with immune checkpoint inhibitors
por: Zhang, Yifan, et al.
Publicado: (2023)

Immune-Related Adverse Events Are Associated With Clinical Benefit in Patients With Non-Small-Cell Lung Cancer Treated With Immunotherapy Plus Chemotherapy: A Retrospective Study
por: Morimoto, Kenji, et al.
Publicado: (2021)

Immune-Related Adverse Events Predict the Efficacy of Immune Checkpoint Inhibitors in Lung Cancer Patients: A Meta-Analysis
por: Wang, Donghui, et al.
Publicado: (2021)

Case Report: A case of synchronous right upper lobe adenocarcinoma and left lower lobe squamous cell carcinoma treated with immune checkpoint inhibitor plus chemotherapy
por: Liu, Yujiao, et al.
Publicado: (2023)

Evaluating Survival After Hospitalization Due to Immune-Related Adverse Events From Checkpoint Inhibitors
por: Silverstein, Jordyn, et al.
Publicado: (2023)

Comparative Risk of Renal Adverse Events in Patients Receiving Immune Checkpoint Inhibitors: A Bayesian Network Meta-Analysis
por: Liu, Kang, et al.
Publicado: (2021)

Arthralgia adverse events due to immune-checkpoint inhibitors for lung cancer patients: a systematic review and meta-analysis
por: Zou, Defang, et al.
Publicado: (2023)

Retrospective study of efficacy and adverse events of immune checkpoint inhibitors in 22 xeroderma pigmentosum patients with metastatic or unresectable cancers
por: Fernandez, Elvelyn R., et al.
Publicado: (2023)

Immune Checkpoint Inhibitors Plus Single-Agent Chemotherapy for Advanced Non-Small-Cell Lung Cancer After Resistance to EGFR-TKI
por: Deng, Haiyi, et al.
Publicado: (2021)

Development and Validation of a Nomogram for Predicting Prognosis to Immune Checkpoint Inhibitors Plus Chemotherapy in Patients With Non-Small Cell Lung Cancer
por: Zeng, Hao, et al.
Publicado: (2021)

Toxicities of Immune Checkpoint Inhibitors: Itis-Ending Adverse Reactions and More
por: Ellithi, Moataz, et al.
Publicado: (2020)

Association of Immune Related Adverse Events With Efficacy of Immune Checkpoint Inhibitors and Overall Survival in Cancers: A Systemic Review and Meta-analysis
por: Fan, Yong, et al.
Publicado: (2021)

Dynamic gut microbiota changes in patients with advanced malignancies experiencing secondary resistance to immune checkpoint inhibitors and immune-related adverse events
por: Zeng, Yanlin, et al.
Publicado: (2023)

Clinical characteristics of gastrointestinal immune-related adverse events of immune checkpoint inhibitors and their association with survival
por: Yamada, Kentaro, et al.
Publicado: (2021)

Ocular adverse events with immune checkpoint inhibitors
por: Fang, Tony, et al.
Publicado: (2019)

Mucocutaneous adverse events to immune checkpoint inhibitors
por: Muhaj, Fiorinda, et al.
Publicado: (2023)

Unexpected Adverse Events of Immune Checkpoint Inhibitors
por: Shalata, Walid, et al.
Publicado: (2023)

Patients with melanoma treated with immune checkpoint inhibitors who had non-thyroid endocrine and skin immune-related adverse events have better prognosis: A systematic review and meta-analysis
por: Sun, Qian, et al.
Publicado: (2022)

Late cardiac adverse events in patients with cancer treated with immune checkpoint inhibitors
por: Dolladille, Charles, et al.
Publicado: (2020)

Insights Into the Host Contribution of Endocrine Associated Immune-Related Adverse Events to Immune Checkpoint Inhibition Therapy
por: Chye, Adrian, et al.
Publicado: (2022)

Redefine Hyperprogressive Disease During Treatment With Immune-Checkpoint Inhibitors in Patients With Gastrointestinal Cancer
por: Wang, Zhenghang, et al.
Publicado: (2021)

Neoadjuvant immune checkpoint inhibitor plus chemotherapy in rare tracheal tumors
por: Jiang, Ben‐Yuan, et al.
Publicado: (2021)

Treatment- and immune-related adverse events of immune checkpoint inhibitors in esophageal or gastroesophageal junction cancer: A network meta-analysis of randomized controlled trials
por: Zheng, Jianqing, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_v0lnqa1h58stv2ldg02c6rfbp6